Nectar Lifesciences Limited has informed the Exchange regarding 'Certification of Good Manufacturing Practices for Medicinal products by State Service of Ukraine on Medicines and Drugs Control (SMDC)'.
NECLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Nectar Lifesciences has received Good Manufacturing Practices (GMP) certification from Ukraine's State Service of Medicines and Drugs Control (SMDC) for its Unit VI located in Baddi, Himachal Pradesh. The certification follows PIC/S Guide, EU Directives, and WHO recommendations, allowing products from this unit to be sold domestically or exported to Ukraine. The certification is valid until April 18, 2026. Notably, shareholders have already approved the slump sale of Unit VI, which was disclosed in earlier filings dated July 7 and August 4, 2025.
This certification could enhance the value and export readiness of Unit VI ahead of its planned slump sale, potentially making it more attractive to buyers. For ongoing shareholders, the direct operational impact is limited since the unit is being divested.